Player FM ऐप के साथ ऑफ़लाइन जाएं!
Chimeric Therapeutics (ASX: CHM) achieves significant progress with latest brain cancer treatment trial (w/ Jennifer Chow)
Manage episode 380645567 series 2701497
Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial.
The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates.
Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up.
This is in direct comparison to survival expectations of around 7 months for patients after first line therapy.
Data obtained from the dose escalation program has provided highly encouraging results, particularly with a number of participants considered very late stage cancer patients.
Chimeric is now opened enrolment for the phase 1B stage of the trials.
Articles:
https://smallcaps.com.au/chimeric-therapeutics-positive-interim-data-cltx-car-t-brain-cancer-trial/
https://smallcaps.com.au/chimeric-therapeutics-chm-0201-cell-study-treatments-acute-myeloid-leukaemia/
https://smallcaps.com.au/chimeric-therapeutics-completes-further-dosing-brain-cancer-clinical-trial/
https://smallcaps.com.au/imugene-worldwide-licence-cd19-cell-therapy-treat-relapsed-cancer-patients/
For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/asx-chm/
See omnystudio.com/listener for privacy information.
125 एपिसोडस
Manage episode 380645567 series 2701497
Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial.
The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates.
Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up.
This is in direct comparison to survival expectations of around 7 months for patients after first line therapy.
Data obtained from the dose escalation program has provided highly encouraging results, particularly with a number of participants considered very late stage cancer patients.
Chimeric is now opened enrolment for the phase 1B stage of the trials.
Articles:
https://smallcaps.com.au/chimeric-therapeutics-positive-interim-data-cltx-car-t-brain-cancer-trial/
https://smallcaps.com.au/chimeric-therapeutics-chm-0201-cell-study-treatments-acute-myeloid-leukaemia/
https://smallcaps.com.au/chimeric-therapeutics-completes-further-dosing-brain-cancer-clinical-trial/
https://smallcaps.com.au/imugene-worldwide-licence-cd19-cell-therapy-treat-relapsed-cancer-patients/
For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/asx-chm/
See omnystudio.com/listener for privacy information.
125 एपिसोडस
सभी एपिसोड
×प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।